Fig. 2From: Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinomaThe dynamic imaging responses of all irradiated and non-irradiated lesions (patients # 1, # 4 and #5)Back to article page